- Opthea Limited has discontinued the development of sozinibercept for neovascular age-related macular degeneration (nAMD).
- The drug did not demonstrate significant improvements in vision compared to standard nAMD treatments in the COAST and ShORe trials.
- The decision could impact Opthea’s solvency.
Source: Retinal Physician
